Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a commercial stage
natural-products pharmaceuticals company focused on developing
novel, sustainably derived gastrointestinal products for both human
prescription use and animals on a global basis, announced today
that the Company is exhibiting and presenting at the Western
Organic Dairy Producers Alliance Conference this week in Sparks,
Nevada to promote Neonorm™ Calf, one of Jaguar’s lead
non-prescription animal products, to organic dairy producers
located throughout the western U.S.
Headquartered in Chico, California, the Western Organic Dairy
Producers Alliance (WODPA) is a nonprofit organization dedicated to
preserving, protecting, and ensuring the sustainability and
integrity of organic dairy farming across the west. WODPA’s
conference is an annual event designed to help organic dairy
farmers stay informed about the organic dairy business.
As Jaguar announced this past June, the Organic Materials Review
Institute (OMRI) has reviewed Neonorm™ Calf and determined that it
is allowed for use in compliance with the U.S. Department of
Agriculture (USDA) National Organic Program. OMRI is an
international nonprofit organization that determines which input
products are allowed for use in organic production and
processing.
Neonorm™ Calf has been formulated and clinically tested to help
proactively retain fluid in dairy calves and reduce the severity of
diarrhea—aiding calves in avoiding debilitating, dangerous levels
of dehydration associated with scours. Neonorm™ is a standardized
botanical extract derived from the Croton lechleri tree, which is
sustainably harvested.
According to data announced April 19, 2017 by the USDA, the
organic industry continues to grow domestically and globally, with
24,650 certified organic operations in the United States, and
37,032 around the world. The USDA’s 2016 count of U.S. certified
organic farms and businesses reflects a 13 percent increase between
the end of 2015 and 2016, continuing the trend of double digit
growth in the organic sector. A report published by Allied Market
Research states that the global market for organic dairy food and
drinks—organic milk, yogurt, cheese, and others—is expected to grow
at a compound annual growth rate of 14.25% from 2016 to reach $36.7
billion by 2022 from $14.5 billion in 2015.
According to the Organic Trade Association’s (OTA’s) 2017
Organic Industry Survey, “The robust American organic sector stayed
on its upward trajectory in 2016, gaining new market share and
shattering records, as consumers across the United States ate and
used more organic products than ever before. Organic sales in the
U.S. totaled around $47 billion in 2016, reflecting new sales of
almost $3.7 billion from the previous year. The $43 billion in
organic food sales marked the first time the American organic food
market has broken though the $40-billion mark. Organic food now
accounts for more than five percent—5.3 percent to be exact—of
total food sales in this country, another significant first for
organic.”
Kathie Arnold, a dairy farmer at Twin Oaks Dairy—a Truxton, NY
dairy farm that has been certified organic since 1998—recently
commented, “Neonorm™ Calf gives us another welcome tool in the
toolbox for our certified organic calves.”
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage natural-products
pharmaceuticals company focused on developing novel, sustainably
derived gastrointestinal products for both human prescription use
and animals on a global basis. Our wholly-owned subsidiary, Napo
Pharmaceuticals, Inc., focuses on developing and commercializing
proprietary human gastrointestinal pharmaceuticals for the global
marketplace from plants used traditionally in rainforest areas. Our
Mytesi® (crofelemer) product is approved by the U.S. FDA for the
symptomatic relief of noninfectious diarrhea in adults with
HIV/AIDS on antiretroviral therapy. Mytesi® is in development for
multiple possible follow-on indications, including cancer
therapy-related diarrhea; orphan-drug indications for infants and
children with congenital diarrheal disorders and short bowel
syndrome; supportive care for inflammatory bowel disease (IBD);
irritable bowel syndrome (IBS); and as a second-generation
anti-secretory agent for use in cholera patients. Canalevia™ is our
lead animal prescription drug candidate, intended for treatment of
various forms of diarrhea in dogs. Equilevia™ is Jaguar’s
non-prescription product for total gut health in equine athletes.
Canalevia™ and Equilevia™ contain ingredients isolated and purified
from the Croton lechleri tree, which is sustainably harvested.
Neonorm™ Calf and Neonorm™ Foal are Jaguar’s lead non-prescription
animal products. Mytesi®, Canalevia™, Equilevia™ and Neonorm™ are
distinct products that act at the same last step in a physiological
pathway generally present in mammals.
For more information about Jaguar, please visit jaguar.health.
For more information about Napo, visit napopharma.com.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated
for the treatment of infectious diarrhea. Rule out infectious
etiologies of diarrhea before starting Mytesi®. If infectious
etiologies are not considered, there is a risk that patients with
infectious etiologies will not receive the appropriate therapy and
their disease may worsen. In clinical studies, the most common
adverse reactions occurring at a rate greater than placebo were
upper respiratory tract infection (5.7%), bronchitis (3.9%), cough
(3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are
available at Mytesi.com. Crofelemer, the active ingredient in
Mytesi®, is a botanical (plant-based) drug extracted and purified
from the red bark sap of the medicinal Croton lechleri tree in the
Amazon rainforest. Napo has established a sustainable harvesting
program for crofelemer to ensure a high degree of quality and
ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
planned, potential follow-on indications for Mytesi®. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this release are only predictions. Jaguar has based
these forward-looking statements largely on its current
expectations and projections about future events. These
forward-looking statements speak only as of the date of this
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise
any forward-looking statements contained herein, whether as a
result of any new information, future events, changed circumstances
or otherwise.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171116005862/en/
Jaguar Health, Inc.Peter Hodgephodge@jaguar.health
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Apr 2023 to Apr 2024